JP7824953B2 - 前立腺がんの治療のためのｃｙｐ１１ａ１阻害薬としての２，３－ジヒドロ－４ｈ－ベンゾ［ｂ］［１，４］オキサジン－４－イル）（５－（フェニル）－ピリジン－３－イル）メタノン誘導体および類似化合物 - Google Patents

前立腺がんの治療のためのｃｙｐ１１ａ１阻害薬としての２，３－ジヒドロ－４ｈ－ベンゾ［ｂ］［１，４］オキサジン－４－イル）（５－（フェニル）－ピリジン－３－イル）メタノン誘導体および類似化合物

Info

Publication number
JP7824953B2
JP7824953B2 JP2023533363A JP2023533363A JP7824953B2 JP 7824953 B2 JP7824953 B2 JP 7824953B2 JP 2023533363 A JP2023533363 A JP 2023533363A JP 2023533363 A JP2023533363 A JP 2023533363A JP 7824953 B2 JP7824953 B2 JP 7824953B2
Authority
JP
Japan
Prior art keywords
compound
methanone
dihydro
alkyl
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023533363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551340A5 (https=
JP2023551340A (ja
Inventor
ベッレ、ダビド ディン
ピエチケイネン、ペッカ
ルマッコ、ペッテリ
ヴォールファールト、ゲルト
Original Assignee
オリオン コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリオン コーポレーション filed Critical オリオン コーポレーション
Publication of JP2023551340A publication Critical patent/JP2023551340A/ja
Publication of JP2023551340A5 publication Critical patent/JP2023551340A5/ja
Application granted granted Critical
Publication of JP7824953B2 publication Critical patent/JP7824953B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023533363A 2020-12-01 2021-11-30 前立腺がんの治療のためのｃｙｐ１１ａ１阻害薬としての２，３－ジヒドロ－４ｈ－ベンゾ［ｂ］［１，４］オキサジン－４－イル）（５－（フェニル）－ピリジン－３－イル）メタノン誘導体および類似化合物 Active JP7824953B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20206226 2020-12-01
FI20206226 2020-12-01
PCT/FI2021/050828 WO2022117920A1 (en) 2020-12-01 2021-11-30 2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and similar compounds as cyp11a1 inhibitors for the treatment of prostate cancer

Publications (3)

Publication Number Publication Date
JP2023551340A JP2023551340A (ja) 2023-12-07
JP2023551340A5 JP2023551340A5 (https=) 2024-12-06
JP7824953B2 true JP7824953B2 (ja) 2026-03-05

Family

ID=78827916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533363A Active JP7824953B2 (ja) 2020-12-01 2021-11-30 前立腺がんの治療のためのｃｙｐ１１ａ１阻害薬としての２，３－ジヒドロ－４ｈ－ベンゾ［ｂ］［１，４］オキサジン－４－イル）（５－（フェニル）－ピリジン－３－イル）メタノン誘導体および類似化合物

Country Status (9)

Country Link
US (1) US20240124431A1 (https=)
EP (1) EP4255902B1 (https=)
JP (1) JP7824953B2 (https=)
KR (1) KR20230117187A (https=)
CN (1) CN116724034A (https=)
AU (1) AU2021391977A1 (https=)
CA (1) CA3200556A1 (https=)
MX (1) MX2023006290A (https=)
WO (1) WO2022117920A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202409023A (zh) * 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
CN121002012A (zh) * 2023-03-29 2025-11-21 西藏海思科制药有限公司 Cyp11a1抑制剂及其用途
CN121039123A (zh) * 2023-04-21 2025-11-28 西藏海思科制药有限公司 Cyp11a1抑制剂及其用途
WO2025021182A1 (en) * 2023-07-27 2025-01-30 Acerand Therapeutics (Hong Kong) Limited Cyp11a1 inhibitors
WO2025051216A1 (zh) * 2023-09-08 2025-03-13 深圳众格生物科技有限公司 一种cyp11a1抑制剂、其制备方法及其应用
WO2025168117A1 (zh) * 2024-02-08 2025-08-14 盛睿泽华医药科技（苏州）有限公司 一种多环化合物及其制备方法和应用
WO2026002207A1 (en) * 2024-06-28 2026-01-02 Acerand Therapeutics (Hong Kong) Limited Heterocyclic compounds as cyp11a1 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020502229A (ja) 2016-12-22 2020-01-23 オリオン コーポレーション Ｃｙｐ１１ａ１（チトクロムｐ４５０モノオキシゲナーゼ１１ａ１）阻害剤としてのピラン誘導体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759379B2 (en) * 2008-01-04 2014-06-24 Gilead Sciences, Inc. Inhibitors of cytochrome P450

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020502229A (ja) 2016-12-22 2020-01-23 オリオン コーポレーション Ｃｙｐ１１ａ１（チトクロムｐ４５０モノオキシゲナーゼ１１ａ１）阻害剤としてのピラン誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
European Journal of Medicinal Chemistry，2019年，180，p.51-61，DOI: 10.1016/j.ejmech.2019.06.079
REGISTRY（STN）[online]，2020年，[検索日2025.09.01]，CAS登録番号 2462832-39-7 他2件

Also Published As

Publication number Publication date
WO2022117920A1 (en) 2022-06-09
EP4255902A1 (en) 2023-10-11
CA3200556A1 (en) 2021-11-30
JP2023551340A (ja) 2023-12-07
MX2023006290A (es) 2023-08-21
KR20230117187A (ko) 2023-08-07
EP4255902B1 (en) 2025-06-04
AU2021391977A1 (en) 2023-07-13
AU2021391977A9 (en) 2024-08-01
US20240124431A1 (en) 2024-04-18
CN116724034A (zh) 2023-09-08

Similar Documents

Publication Publication Date Title
JP7824953B2 (ja) 前立腺がんの治療のためのｃｙｐ１１ａ１阻害薬としての２，３－ジヒドロ－４ｈ－ベンゾ［ｂ］［１，４］オキサジン－４－イル）（５－（フェニル）－ピリジン－３－イル）メタノン誘導体および類似化合物
EP2757884B1 (en) Pyrazolopyridyl compounds as aldosterone synthase inhibitors
AU2015330141B2 (en) Spirodiamine derivatives as aldosterone synthase inhibitors
JP5883501B2 (ja) アルドステロンシンターゼインヒビター
JP2019509978A (ja) Ｒｏｃｋ阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物
EP3119772A1 (en) Heteroaryl sik inhibitors
EP2864330A1 (en) Pyrrolopyrazone inhibitors of tankyrase
WO2022137085A1 (en) Indole derivatives useful in treating conditions associated with cgas
EP2516435B1 (en) Inhibitors of akt activity
EP2757882A1 (en) Imidazopyridyl compounds as aldosterone synthase inhibitors
WO2019094319A1 (en) Pyrrolopyrazine derivatives as alpha v integrin inhibitors
WO2017101796A1 (zh) 酞嗪酮衍生物、其制备方法及用途
JP5937201B2 (ja) ２−アミノ−３−（イミダゾール−２−イル）ピリジン−４−オン誘導体及びｖｅｇｆ受容体キナーゼ阻害剤としてのその使用
EP2757883A1 (en) Triazolopyridyl compounds as aldosterone synthase inhibitors
CN102802629A (zh) 取代的4-羟基嘧啶-5-甲酰胺
JP2025529873A (ja) 線維症
KR20240049811A (ko) Ddr1의 억제제로서 페닐- 및 피리도피라졸 유도체
JP6670832B2 (ja) アルドステロン合成酵素阻害剤としての新規ジヒドロキノリンピラゾリル化合物
JP2025538918A (ja) ヒトアルドステロン合成酵素（ｃｙｐ１１ｂ２）の阻害剤
JP2026507588A (ja) ジヒドロベンズイミダゾロンコアを有するｄｄｒ１およびｄｄｒ２阻害剤
WO2024229221A1 (en) Androgen receptor modulators and methods for their use
EA050143B1 (ru) Ингибиторы альдостеронсинтазы человека (cyp11b2)
HK1235394B (zh) 作为醛固酮合酶抑制剂的螺二胺衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260220

R150 Certificate of patent or registration of utility model

Ref document number: 7824953

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150